Track Incruse Ellipta price changes
Subscribe for DrugPrice updates by email. No spam, unsubscribe anytime.
Why Incruse Ellipta Costs $185.00 Per Claim
Incruse Ellipta (Umeclidinium) is used to treat asthma/copd. According to CMS Medicare Part D spending data, the program spent $345.0M on this drug, covering 224,000 beneficiaries across 1,860,000 claims.
A generic version of this drug is available, which means lower-cost alternatives exist. Patients should ask their pharmacist about generic Umeclidinium or talk to their doctor about therapeutic alternatives that may cost less.
Price Breakdown
Drug Details
Frequently Asked Questions
Incruse Ellipta (Umeclidinium) costs an average of $185.00 per claim based on Medicare Part D data. The estimated annual cost per patient is $1,540.00. Actual out-of-pocket costs depend on your insurance plan and pharmacy.
Incruse Ellipta averages $185.00 per Medicare Part D claim — roughly equivalent to a 30-day supply for most patients on standard dosing. Without insurance, expect higher cash-pay prices unless you use a discount program (GoodRx, SingleCare, manufacturer copay assistance). With Medicare or commercial insurance, your out-of-pocket cost depends on your plan's formulary tier and deductible status.
A typical 30-day supply of Incruse Ellipta reflects in our Medicare Part D average of $185.00 per claim. Switching to generic Umeclidinium typically reduces cost by 80-95%. Cash-pay prices vary by pharmacy — comparison shopping (or using GoodRx coupons) often saves 20-50% off the listed price.
Most commercial insurance plans and Medicare Part D plans cover Incruse Ellipta, but coverage varies by formulary tier. Insurers typically prefer generic Umeclidinium (Tier 1, lowest copay) over brand-name Incruse Ellipta (Tier 2-3, higher copay). Some plans require prior authorization or step therapy. Check your plan's formulary or call the number on your insurance card to confirm.
Several options for cash-pay patients: (1) Manufacturer patient assistance programs — the manufacturer may offer copay cards or free-drug programs for income-qualified patients; (2) Discount programs like GoodRx, SingleCare, or RxSaver typically save 20-80% off the cash price; (3) Mark Cuban's Cost Plus Drugs offers transparent generic pricing if a generic is available; (4) 340B-eligible community health centers offer drugs at federally negotiated discounts. Switching to generic Umeclidinium is the single biggest cost reducer if your prescriber is open to it.
Brand-name Incruse Ellipta costs more than generic Umeclidinium primarily for marketing reasons — patients can request the brand from their doctor even when a chemically identical generic exists. The active ingredient and clinical effect are the same.
Yes, a generic version of Incruse Ellipta (Umeclidinium) is available. Generic medications typically cost 80-95% less than brand-name drugs. Ask your pharmacist about generic Umeclidinium.
Medicare Part D spent $345.0M on Incruse Ellipta, covering 224,000 beneficiaries across 1,860,000 claims. This makes it one of the tracked drugs in the Medicare spending dashboard.
Ask your pharmacist about generic Umeclidinium, which is typically much cheaper. You can also compare prices at different pharmacies, use prescription discount programs (GoodRx, SingleCare, Cost Plus Drugs), or ask your doctor about therapeutic alternatives in the same drug class.
Reading Incruse Ellipta's Medicare Pricing
At $185.00 per claim, Incruse Ellipta is a mid-priced medication — more than a bargain generic but well short of a specialty product. Drugs in this range are often brands with partial competition, recently-genericized molecules still carrying brand pricing, or moderately complex formulations. The cost is real but rarely catastrophic for asthma/copd, and a same-class or generic substitute frequently closes most of the gap.
Incruse Ellipta accounts for $345.0M in Medicare Part D spending — a large line item built from 1,860,000 claims across 224,000 beneficiaries. Whether that total is driven more by price or by volume is the useful question: a high $185.00 average claim cost means price is the lever, a modest one means utilization is. Either way, a drug at this spending level is firmly on plan formulary committees' radar.
Because a generic version of Umeclidinium is on the market, the realistic savings path for Incruse Ellipta is straightforward: the generic is therapeutically equivalent and typically costs a fraction of the brand. The friction is usually prescribing habit rather than availability — patients can ask the prescriber to write for the generic, and most plans already steer to it with a lower copay tier. That single switch usually beats coupons, assistance programs, and pharmacy shopping combined.
Every figure here comes from the CMS Medicare Part D Drug Spending dashboard, which reports what the program paid — not the cash price at a retail pharmacy and not a patient's out-of-pocket cost. List prices also overstate the real economics: manufacturers pay confidential rebates to pharmacy benefit managers, so the net price plans actually pay is often well below the sticker. Treat $185.00 as a consistent Medicare-program benchmark for Incruse Ellipta, useful for comparing drugs on the same basis, rather than the price any one patient will see at the counter.
Related
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims.